Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase IIa Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors

This study has been terminated.
(Lack of efficacy)
Sponsor:
Information provided by (Responsible Party):
Joel Neal, Stanford University
ClinicalTrials.gov Identifier:
NCT01719861
First received: October 29, 2012
Last updated: May 21, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2014
  Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)